Abstract
INTRODUCTION: Cancer is one of the most significant health challenges demanding the expansion of effectual therapeutic methods. Triple-negative breast cancer (TNBC) is a form of aggressive cancer with inadequate therapeutic options which lacks the expression of certain hormones. MATERIALS AND METHODS: The present study investigates the potential of naringenin-7-O-glucoside, a flavanone glycoside extracted from Holarrhena antidysenterica as an anticancer agent against TNBC cell lines. In-vitro analysis to evaluate cytotoxicity, apoptotic-inducing properties and effect on gene expression was conducted. RESULTS: MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay studied the IC-50 of naringenin-7-O-glucoside to be 233.56 µg/µL, revealing the dose-dependent cytotoxicity with minimal effect on Vero cells. Extensive DNA fragmentation confirmed the apoptotic property. Furthermore, a significant downregulation of the epidermal growth factor receptor (EGFR) was noted in treated cells when equated to the control specimen of the sample. CONCLUSION: Therefore, naringenin-7-O-glucoside can be a potential targeted therapeutic agent.